论文部分内容阅读
色瑞替尼(ceritinib)由Novartis Pharms公司研究与开发,于2014年4月29日经美国食品药品监督管理局(FDA)批准上市,商品名为ZykadiaTM,该药为胶囊剂。用于对crizotinib(克唑替尼)治疗后已进展或不能耐受的晚期间变性淋巴瘤激酶阳性(Anaplastic lymphoma kinasepositive,ALK+)转移性非小细胞肺癌(NSCLC)患者的治疗。推荐剂量为每天750 mg[1]。色瑞替尼的中文化学名称:5-氯-N2-(2-异丙氧基-5-甲基-4-(哌啶-4-基)苯基)-N4-(2-(异丙基磺酰基)苯基)嘧啶-
Ceritinib was researched and developed by Novartis Pharms and was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2014 under the trade name ZykadiaTM, which is a capsule. For the treatment of patients with late-stage anaplastic lymphoma kinase positive (ALK +) metastatic non-small cell lung cancer (NSCLC) that have progressed or intolerable after crizotinib (crizotinib) treatment. The recommended dose is 750 mg daily [1]. The Chinese chemical name of ceritinib: 5-chloro-N2- (2-isopropoxy-5-methyl- 4- (piperidin-4- yl) phenyl) -N4- (2- Ylsulfonyl) phenyl) pyrimidine-